Welcome to our dedicated page for Eyenovia SEC filings (Ticker: EYEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eyenovia Inc. filings document the company’s transition to Hyperion DeFi, Inc., including the corporate name change, Nasdaq trading symbol change to HYPD, and common stock registration details. Recent 8-K disclosures cover Regulation FD updates, other events, executive and workforce-related governance matters, and material agreements tied to the company’s public-company status.
The filing record also documents a private placement, registration rights, capital-structure disclosures, and the stated use of proceeds for a HYPE reserve and staking program. Related disclosures address the company’s Hyperliquid validator activity, its cryptocurrency treasury strategy, and continuing references to the Gen-2 Optejet User Filled Device within the legacy ophthalmic technology business.
Eyenovia announced a significant strategic shift through a $50 million private placement and entry into cryptocurrency markets. The company sold 5,128,205 shares of Series A Non-Voting Preferred Stock and warrants to institutional investors, with each preferred share convertible into three common shares.
Key developments include:
- Appointment of Hyunsu Jung (age 29) as Chief Investment Officer and Director, with a $250,000 salary and equity incentives
- Plans to build reserves of HYPE tokens and implement a staking program while continuing development of Gen-2 Optejet Device
- Board restructuring with resignations of Sean Ianchulev, Charles Mather IV, and Ram Palanki
- Amendment to loan agreement with Avenue Capital, extending maturity to 2028 and reducing interest from 12% to 8%
The private placement includes warrants exercisable at $3.25 per share after six months, with Chardan Capital Markets acting as placement agent. The company's pro forma shares outstanding would increase to 54,027,429 upon full conversion of preferred shares and warrant exercise.
Avenue Capital Management II has filed a Schedule 13D/A (Amendment No. 3) regarding their holdings in Eyenovia, reporting significant ownership changes through multiple investment vehicles. The filing reveals:
Key Investment Vehicles & Holdings:
- Avenue Venture Opportunities Fund L.P. owns 174,175 shares (4.0%)
- Avenue Venture Opportunities Fund II L.P. holds 261,263 shares (5.99%)
- Avenue Capital Management II L.P. controls 435,438 shares (9.99%)
The funds collectively hold warrants to purchase an additional 250,000 shares at $4.00 per share, though these are subject to a 9.99% beneficial ownership blocker. Total shares outstanding as of June 5, 2025: 4,358,755. Avenue Capital Management II L.P. serves as the manager with sole voting and dispositive power over all securities held by the funds.